Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects [PDF]
Frontiers in Immunology, 2023 Patients with hematological disorders and severe thrombocytopenia require extensive and iterative platelet transfusion support. In these patients, platelet transfusion refractoriness represents a serious adverse transfusion event with major outcomes for ...
Adèle Couvidou +15 more
doaj +4 more sources
Related donor platelet transfusion improves platelet transfusion refractoriness in hematological patients [PDF]
Frontiers in Medicine, 2023 ObjectiveTransfusion of HLA-matched platelets can reduce the effect of alloimmune responses on platelet transfusion efficacy; however, finding HLA-matched platelets in the population is nearly impossible. Almost all HLA-matched platelets from related are
Jing-Cheng Zhang +3 more
doaj +4 more sources
Avatrombopag for the salvage treatment of platelet transfusion refractoriness [PDF]
Therapeutic Advances in HematologyBackground: Platelet transfusion refractoriness (PTR) is a life-threatening and intractable condition in hematological patients. Thrombopoietin receptor agonists such as avatrombopag promote platelet production and modulate immune intolerance.
Yuehong Qin +4 more
doaj +4 more sources
Extent of transfusion support in a developing country in managing a bleeding acute myeloid leukemia patient with platelet transfusion refractoriness [PDF]
Asian Journal of Transfusion Science, 2021 Conventional platelet transfusion may not be adequate to deal with platelet transfusion refractoriness (PTR), and therefore human leukocyte antigen (HLA) or human platelet antigen (HPA) matched and platelet crossmatch compatible units are recommended ...
Gayathiri K Chellaiya +5 more
doaj +2 more sources
Evaluation and management of platelet transfusion refractoriness. [PDF]
Blood Res, 2022 Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types: immune and non-immune. Most cases of PTR are non-immune. Among immune causes, the most common
Youk HJ, Hwang SH, Oh HB, Ko DH.
europepmc +3 more sources
Prevalence, Risk Factors, and Outcomes of Platelet Transfusion Refractoriness in Critically Ill Patients: A Retrospective Cohort Study [PDF]
Critical Care Research and Practice, 2021 Background. Refractoriness to platelet transfusion is an understudied phenomenon in critically ill patients. Our objective was to evaluate the prevalence, risk factors, and clinical outcomes of platelet refractoriness among patients in a tertiary-care ...
Saeed Arabi +5 more
doaj +2 more sources
Platelet transfusion refractoriness [PDF]
British Journal of Haematology, 2008 SummaryThe platelet, a fascinating anucleate cell, is critically important for haemostasis. Platelet transfusions have greatly reduced the incidence of major haemorrhagic complications associated with the management of haematological and oncological disorders. However, some patients fail to receive the full benefit of platelet transfusions because they
Eldad Hod
exaly +3 more sources
Platelet Transfusion Refractoriness
PlasmatologyPlatelet transfusion refractoriness (PTR) is a conditioikb1n where platelet counts fail to increase adequately in several transfusions, often found in hemato-oncological situations.
Anna Mira Lubis MD +2 more
doaj +2 more sources
Mechanism and transfusion strategy of immunogenic platelet transfusion refractoriness
Zhongguo shuxue zazhi, 2022 Platelet transfusion is an irreplaceable method to treat patients with platelet reduction in Hematology Department and Oncology Department. However, immunogenic platelet transfusion refractoriness is a huge challenge to patients who require repeatedly ...
Juan SAI, Li TIAN
doaj +2 more sources
Severe platelet transfusion refractoriness after thoracoabdominal aneurysm repair [PDF]
Journal of Vascular Surgery Cases and Innovative TechniquesSevere thrombocytopenia after thoracoabdominal aortic aneurysm repair poses a significant clinical risk in the immediate postoperative period.
Claire M. Motyl, MD +3 more
doaj +2 more sources